FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2300896737> ?p ?o ?g. }

• W2300896737 endingPage "20690" @default.
• W2300896737 startingPage "20680" @default.
• W2300896737 abstract "// Li Lin 1, * , Ji-Jin Yao 1, * , Guan-Qun Zhou 1 , Rui Guo 1 , Fan Zhang 1 , Yuan Zhang 1 , Lin Xu 1 , Lu-Lu Zhang 1 , Ai-Hua Lin 2 , Jun Ma 1 , Ying Sun 1 1 Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People’s Republic of China 2 Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, People’s Republic of China * These authors have contributed equally to this work Correspondence to: Ying Sun, e-mail: sunying@sysucc.org.cn Keywords: nasopharyngeal carcinoma, intensity modulated radiotherapy, individualized clinical target volume, clinical outcome, toxicities Received: October 10, 2015      Accepted: February 18, 2016      Published: March 09, 2016 ABSTRACT Background: To evaluate the efficacy and toxicity of intensity-modulated radiotherapy (IMRT) using individualized clinical target volumes (CTVs) based on the loco-regional extension patterns of nasopharyngeal carcinoma (NPC). Methods: From December 2009 to February 2012, 220 patients with histologically-proven, non-disseminated NPC were prospectively treated with IMRT according to an individualized delineation protocol. CTV1 encompassed the gross tumor volume, entire nasopharyngeal mucosa and structures within the pharyngobasilar fascia with a margin. CTV2 encompassed bilateral high risk anatomic sites and downstream anatomic sites adjacent to primary tumor, bilateral retropharyngeal regions, levels II, III and Va, and prophylactic irradiation was gave to one or two levels beyond clinical lymph nodes involvement. Clinical outcomes and toxicities were evaluated. Results: Median follow-up was 50.8 (range, 1.3–68.0) months, four-year local relapse-free, regional relapse-free, distant metastasis-free, disease-free and overall survival rates were 94.7%, 97.0%, 91.7%, 87.2% and 91.9%, respectively. Acute severe (≥ grade 3) mucositis, dermatitis and xerostomia were observed in 27.6%, 3.6% and zero patients, respectively. At 1 year, xerostomia was mild, with frequencies of Grade 0, 1, 2 and 3 xerostomia of 27.9%, 63.3%, 8.3% and 0.5%, respectively. Conclusions: IMRT using individualized CTVs provided high rates of local and regional control and a favorable toxicity profile in NPC. Individualized CTV delineation strategy is a promising one that may effectively avoid unnecessary or missed irradiation, and deserve optimization to define more precise individualized CTVs." @default.
• W2300896737 created "2016-06-24" @default.
• W2300896737 creator A5020243059 @default.
• W2300896737 creator A5026936543 @default.
• W2300896737 creator A5036630445 @default.
• W2300896737 creator A5053447705 @default.
• W2300896737 creator A5054603016 @default.
• W2300896737 creator A5055912468 @default.
• W2300896737 creator A5067575942 @default.
• W2300896737 creator A5069750573 @default.
• W2300896737 creator A5070961992 @default.
• W2300896737 creator A5075472501 @default.
• W2300896737 creator A5080448292 @default.
• W2300896737 date "2016-03-09" @default.
• W2300896737 modified "2023-10-03" @default.
• W2300896737 title "The efficacy and toxicity of individualized intensity-modulated radiotherapy based on the tumor extension patterns of nasopharyngeal carcinoma" @default.
• W2300896737 cites W1492772022 @default.
• W2300896737 cites W1557058721 @default.
• W2300896737 cites W1767632608 @default.
• W2300896737 cites W1965525170 @default.
• W2300896737 cites W1977143597 @default.
• W2300896737 cites W1987104299 @default.
• W2300896737 cites W1993307199 @default.
• W2300896737 cites W1997391888 @default.
• W2300896737 cites W2005887998 @default.
• W2300896737 cites W2017276054 @default.
• W2300896737 cites W2019419382 @default.
• W2300896737 cites W2024847643 @default.
• W2300896737 cites W2037410430 @default.
• W2300896737 cites W2039612363 @default.
• W2300896737 cites W2043945205 @default.
• W2300896737 cites W2045352770 @default.
• W2300896737 cites W2046664458 @default.
• W2300896737 cites W2054504841 @default.
• W2300896737 cites W2059775855 @default.
• W2300896737 cites W2062338389 @default.
• W2300896737 cites W2062438065 @default.
• W2300896737 cites W2106787323 @default.
• W2300896737 cites W2111714525 @default.
• W2300896737 cites W2113470349 @default.
• W2300896737 cites W2119018166 @default.
• W2300896737 cites W2132568136 @default.
• W2300896737 cites W2141988766 @default.
• W2300896737 cites W2146900413 @default.
• W2300896737 cites W2167359560 @default.
• W2300896737 cites W2917837889 @default.
• W2300896737 cites W4239554024 @default.
• W2300896737 cites W4245162655 @default.
• W2300896737 doi "https://doi.org/10.18632/oncotarget.8004" @default.
• W2300896737 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4991484" @default.
• W2300896737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26980744" @default.
• W2300896737 hasPublicationYear "2016" @default.
• W2300896737 type Work @default.
• W2300896737 sameAs 2300896737 @default.
• W2300896737 citedByCount "13" @default.
• W2300896737 countsByYear W23008967372016 @default.
• W2300896737 countsByYear W23008967372018 @default.
• W2300896737 countsByYear W23008967372019 @default.
• W2300896737 countsByYear W23008967372020 @default.
• W2300896737 countsByYear W23008967372021 @default.
• W2300896737 countsByYear W23008967372022 @default.
• W2300896737 countsByYear W23008967372023 @default.
• W2300896737 crossrefType "journal-article" @default.
• W2300896737 hasAuthorship W2300896737A5020243059 @default.
• W2300896737 hasAuthorship W2300896737A5026936543 @default.
• W2300896737 hasAuthorship W2300896737A5036630445 @default.
• W2300896737 hasAuthorship W2300896737A5053447705 @default.
• W2300896737 hasAuthorship W2300896737A5054603016 @default.
• W2300896737 hasAuthorship W2300896737A5055912468 @default.
• W2300896737 hasAuthorship W2300896737A5067575942 @default.
• W2300896737 hasAuthorship W2300896737A5069750573 @default.
• W2300896737 hasAuthorship W2300896737A5070961992 @default.
• W2300896737 hasAuthorship W2300896737A5075472501 @default.
• W2300896737 hasAuthorship W2300896737A5080448292 @default.
• W2300896737 hasBestOaLocation W23008967371 @default.
• W2300896737 hasConcept C126322002 @default.
• W2300896737 hasConcept C143998085 @default.
• W2300896737 hasConcept C2778997737 @default.
• W2300896737 hasConcept C509974204 @default.
• W2300896737 hasConcept C71924100 @default.
• W2300896737 hasConceptScore W2300896737C126322002 @default.
• W2300896737 hasConceptScore W2300896737C143998085 @default.
• W2300896737 hasConceptScore W2300896737C2778997737 @default.
• W2300896737 hasConceptScore W2300896737C509974204 @default.
• W2300896737 hasConceptScore W2300896737C71924100 @default.
• W2300896737 hasIssue "15" @default.
• W2300896737 hasLocation W23008967371 @default.
• W2300896737 hasLocation W23008967372 @default.
• W2300896737 hasLocation W23008967373 @default.
• W2300896737 hasLocation W23008967374 @default.
• W2300896737 hasOpenAccess W2300896737 @default.
• W2300896737 hasPrimaryLocation W23008967371 @default.
• W2300896737 hasRelatedWork W2052574963 @default.
• W2300896737 hasRelatedWork W2356227442 @default.
• W2300896737 hasRelatedWork W2356304706 @default.
• W2300896737 hasRelatedWork W2359001965 @default.
• W2300896737 hasRelatedWork W2373838676 @default.
• W2300896737 hasRelatedWork W2375776487 @default.

• next